You have 9 free searches left this month | to do more

cpi-613

Cpi 613 is a drug used to treat Cancer, Lymphoma, Acute Myeloid Leukemia (AML), and other conditions. Cpi 613 is being actively studied in 2 studies and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
Rafael Pharmaceuticals Inc.Eastchester Center for Cancer Care
Wake Forest University Health SciencesMary Crowley Cancer Research Centers
Memorial Sloan Kettering Cancer CenterBritish Columbia Cancer Agency
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
R
Not yet recruiting
  • C04.588.274.476.411.307
  • CPI-613
  • +2 more
  • (no location specified)
2021-09-27
Sep 27, 2021
W
Withdrawn
  • Myelodysplastic Syndromes
  • Progressive Disease
  • Buffalo, New York
  • +1 more
2021-04-08
Apr 8, 2021
S
Withdrawn
  • Pancreatic Ductal Adenocarcinoma
  • (no location specified)
2018-08-20
Aug 20, 2018
W
Completed
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • +6 more
  • CPI-613
  • +4 more
  • Winston-Salem, North Carolina
    Comprehensive Cancer Center of Wake Forest University
2018-06-29
Jun 29, 2018
R
Completed
  • Advanced Cancer
  • +4 more
  • CPI-613
  • Peoria, Arizona
  • +3 more
2016-12-28
Dec 28, 2016
R
Terminated
  • Cancer
  • CPI-613
  • Bronx, New York
    Eastchester Center for Cancer Care
2016-12-27
Dec 27, 2016
R
Withdrawn
  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • CPI-613
  • Cranbury, New Jersey
    Cornerstone Pharmaceuticals, Inc
2016-12-27
Dec 27, 2016
R
Withdrawn
  • Metastatic Pancreatic Adenocarcinoma
  • CPI-613
  • +2 more
  • Bronx, New York
  • +1 more
2013-08-13
Aug 13, 2013